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Phase II Trial of Pralatrexate
(10-Propargyl-10-deazaaminopterin, PDX) in Patients
with Unresectable Malignant Pleural Mesothelioma
Lee M. Krug, MD,* Robert T. Heelan, MD,† Mark G. Kris, MD,*
Ennapadam Venkatraman, PhD,‡ and F.M. Sirotnak, PhD§
Background: Several previous clinical trials have shown that malig-
nant pleural mesothelioma is responsive to antifolates. The dihydrofo-
late reductase inhibitor, pralatrexate, has a favorable toxicity profile,
primarily limited to stomatitis, and has demonstrated activity in patients
with non-small cell lung cancer. In mesothelioma cell lines and xeno-
grafts, pralatrexate demonstrated significant antitumor activity.
Methods: We conducted this phase II study to determine the
response rate of malignant pleural mesothelioma to pralatrexate at a
dose of 135 mg/m2 IV every 2 weeks. After a protocol amendment,
patients were supplemented with vitamin B12 and folic acid at the
time of starting therapy.
Results: A total of 16 assessable patients were enrolled. No com-
plete or partial responses were observed. Two patients with epithe-
lioid histology had minor responses. Three other patients remained
on study with stable disease for 9, 9, and 48 months. The median
time to progression was 3 months. The overall median survival time
was 7 months (95% confidence interval: 3.2–16.2 months) and the
one-year survival was 31% (95% confidence interval: 15%–65%).
Three patients (19%) had grade 2 stomatitis, eight (50%) had grade
3, and one (6%) had grade 4.
Conclusions:With this particular dose and schedule, pralatrexate as
a single agent had no activity in malignant pleural mesothelioma.
Key Words: Pralatrexate, 10-Propargyl-10-deazaaminopterin, or
PDX, Mesothelioma, Antifolate.
(J Thorac Oncol. 2007;2: 317–320)
Malignant mesothelioma arising from the parietal pleuraafflicts 2000 to 3000 Americans annually.1 All known
treatment modalities, including surgery, radiation, and che-
motherapy, have little effect on survival. Chemotherapy, in
particular, has historically been inadequate. Phase II studies
generally show response rates to chemotherapy of less than
15% and median survival times of 6 to 10 months.2 As a
class, the antifolates stand out as showing somewhat more
efficacy than others.3–7 In phase III studies, pemetrexed6 and
raltitrexed5 improved survival when combined with cisplatin.
Pemetrexed and cisplatin became the first and only chemo-
therapy regimen approved by the U.S. Food and Drug Ad-
ministration for this disease in 2004.
In this study, we evaluated the efficacy of the anti-
folate pralatrexate (otherwise known as 10-propargyl-10-
deazaaminopterin, or PDX) in patients with mesothelioma.
Pralatrexate, an inhibitor of dihydrofolate reductase, has
greater affinity for the RFC-1 folate transporter and folyl-
polyglutamate synthetase than other antifolates.8 In addition
to the superior antitumor activity observed in human breast
and lung cancer cell lines and xenografts, pralatrexate shows
significant cytotoxicity against mesothelioma.9,10 Pralatrexate
inhibited the growth of VAMT-1 and JMN mesothelioma cell
lines 25 to 30 times better than methotrexate and three times
better than edatrexate. In established JMN xenografts in nude
mice, pralatrexate induced tumor shrinkage and complete
remission, neither of which was observed with methotrexate
or edatrexate. The antitumor effects were even greater when
pralatrexate was combined with cisplatin or carboplatin. Clin-
ically, pralatrexate exhibited an excellent safety profile in a
phase I trial, with a primary toxicity of stomatitis and no
significant myelosuppression.11 Furthermore, antitumor ac-
tivity was demonstrated in a phase II trial of non-small cell
lung cancer.12
PATIENTS AND METHODS
Chemotherapy-naive patients with unresectable malig-
nant pleural mesothelioma were eligible. After an amend-
ment, patients who had received one previous chemotherapy
regimen (but not with an antifolate) were also eligible. Pa-
tients were required to have a Karnofsky performance status
of 70%. Measurable or evaluable indicator lesions that had
not been irradiated were necessary. Laboratory parameters
included a white blood cell count 4000/l, hemoglobin
10 g/dl, platelet count 160/l, total bilirubin 1.0 mg/dl,
aspartate aminotransferase 1.5  upper limits of normal
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(ULN), alkaline phosphatase 5  ULN, and creatinine
1.5 mg/dl or creatinine clearance 50 mg/min/1.7 m2.
Because of the potential for drug accumulation in fluid
collections, patients with clinically significant pleural effu-
sions or ascites, grade 3 or 4 edema, or previous pneumonec-
tomy were excluded. Patients with a concurrent active cancer
or uncontrolled brain or leptomeningeal disease were also
excluded. This protocol was reviewed by the Institutional
Review Board at Memorial Sloan-Kettering Cancer Center.
All patients signed an informed consent document.
Based on the dose used in the phase II trial in non-small
cell lung cancer, patients were treated with pralatrexate at 135
mg/m2 intravenous push every 2 weeks. Two treatments were
defined as one cycle (4 weeks). Patients had a computed
tomography scan to evaluate for response after the first cycle
and then every two cycles thereafter. Modified Response
Evaluation Criteria in Solid Tumors were used to assess re-
sponse.13 Toxicities were graded using the National Cancer
Institute Common Toxicity Criteria version 2.0. Patients with
mucositis on the day of treatment were held for a week until
resolution. Patients with grade 3 or higher mucositis at any time
were treated on subsequent cycles with a 50% dose reduction.
A Simon two-stage design was employed to calculate
sample size.14 With an unacceptable response rate (p0) of
0.05, a desirable response rate (p1) of 0.20 and with  and 
errors of 0.10, the initial cohort of 12 patients would be
enrolled, expanded to 37 patients if one or more partial
responses were observed.
When this trial opened, there were concerns that vita-
min supplementation would lessen the activity of pralatrex-
ate. This was based on two sequential Cancer and Leukemia
Group B studies in mesothelioma in which a lower response
rate and survival time occurred when leucovorin was added to
edatrexate.3 For this reason, patients were instructed to dis-
continue any folic acid supplementation, including in multi-
vitamins, for 7 days before starting therapy. Only after
patients developed stomatitis would they initiate folic acid
supplementation. However, subsequent reports supported the
use of vitamin B12 and folic acid supplementation with
pemetrexed, which lessened side effects without diminishing
efficacy.6,15 Furthermore, in an LX-1 lung cancer xenograft
model, folic acid supplementation did not adversely affect
tumor response to pralatrexate (F.M. Sirotnak, unpublished
data). As a result, this trial was amended (after the first nine
patients had been enrolled) to add vitamin supplementation.
Patients received folic acid 1 mg orally daily and vitamin B12
1000 g intramuscularly beginning at least 7 days before
starting pralatrexate. Folic acid continued daily and vitamin
B12 was administered every 9 weeks. The trial was expanded
so that 12 patients treated with vitamin premedications would
be enrolled in the first cohort. Folate levels were measured for
all patients at baseline. Homocysteine serum concentrations
were measured at baseline and before each cycle. Methylma-
lonic acid levels were not collected.
RESULTS
From August of 2001 to June of 2004, 17 patients were
enrolled. The characteristics of the 16 patients who are
TABLE 1. Patient Characteristics (n  16)
Median Age, y (range) 71 (49–86)
Females 3 (19%)
Performance status
90% 3 (19%)
80% 8 (50%)
70% 5 (31%)
Histology
Epithelioid 11 (69%)
Biphasic 4 (25%)
Desmoplastic 1 (6%)
Previous treatment
None 15 (94%)
Gemcitabine/carboplatin 1 (6%)
FIGURE 1. Kaplan-Meier survival
curve. Median survival  6.8
months (95% CI 3.2–16.2
months); 1-year survival  31%
(95% CI 5–65%). CI, confidence
interval.
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assessable for response and toxicity are listed in Table 1. One
patient who withdrew consent before starting treatment is not
included. The median age was 71 (range, 49–86) with three
patients 80 years old or older. Three patients (19%) were
female. Eleven (69%) had epithelioid histology, four (25%)
biphasic, and one (6%) desmoplastic.
No complete or partial responses were observed (0%
observed rate, 95% confidence interval: 0–21%). Two pa-
tients with epithelioid histology had minor tumor shrinkage
that did not meet criteria for response. One of these patients
was taken off study due to severe stomatitis, and after
re-evaluation, she underwent a complete surgical resection
followed by hemithoracic radiation; she remained disease
free for 2 years. The second patient continued on study for a
total of 31 months. Three other patients remained on study
with stable disease for 9, 9, and 48 months. All these patients
were in the first cohort, and all but one required dose
reduction and vitamin supplementation due to toxicity.
The median time to progression was 3 months. The
overall median survival was 7 months (95% confidence
interval: 3.2–16.2 months). The 1-year survival was 31%
(95% confidence interval: 15%–65%). The Kaplan-Meier
survival curve is shown in Figure 1. The sample size is too
small to elucidate any difference in survival or other outcome
measures between the groups of patients who were or were
not supplemented with vitamins.
Toxicities
The primary toxicity of pralatrexate was stomatitis
(Table 2). Three patients (19%) had grade 2 stomatitis, eight
(50%) had grade 3, and one (6%) had grade 4. Every patient
treated without vitamins developed at least grade 2 stomatitis.
Conversely, four of seven patients who received vitamin
supplementation had no stomatitis, but the other three had
grade 3. One patient developed an ulceration on his penis
(grade 3) deemed related to study drug. One patient died of
Clostridium difficile colitis shortly after coming off study for
disease progression. The mean serum homocysteine concen-
trations did not differ for patients with stomatitis (11.85
M/l, n  4) or without stomatitis (11.5 M/l, n  11).
Because some patients had serum folate concentrations and
others had red blood cell folate concentrations at baseline, no
conclusion could be drawn about the correlation of these and
stomatitis.
DISCUSSION
This phase II trial evaluated the activity and toxicity of
the antifolate pralatrexate in patients with malignant pleural
mesothelioma. No responses were observed, although several
patients were on treatment for an extended period of time,
including two patients treated for 31 and 48 months.
The activity of pralatrexate as a single agent at this dose
and schedule appears to be less than that observed with
pemetrexed which had a 14% response rate in a phase II
single-agent trial.16 One explanation may be that inhibition of
other enzymes involved with folate metabolism accounts
for the greater activity of pemetrexed. Pemetrexed primar-
ily inhibits thymidylate synthase but also inhibits dihydro-
folate reductase and glycinamide ribonucleotide formyl-
transferase.17 However, raltitrexed, which selectively inhibits
thymidylate synthase, has also been shown to improve sur-
vival for patients with mesothelioma when given in combi-
nation with cisplatin.5 Other factors need to be considered.
First, this study with pralatrexate included a challenging
cohort of patients, with three octogenarians (19%) and five
patients (31%) with nonepithelioid histology. Second, a high
rate of toxicity may have affected drug delivery of pralatrex-
ate. Every patient treated without previous vitamin B12 and
folic acid had at least grade 2 stomatitis, and dose reductions
were necessary for the patients who stayed on study after the
first cycle. Of the patients managed with vitamin supplemen-
tation from the outset, four of seven had no stomatitis,
although it was severe (grade 3) in the patients who did
experience it. As a comparison, in the previous phase II trial
TABLE 2. Toxicities Possibly or Definitely Related to
Pralatrexate (as graded using Common Toxicity Criteria
version 2.0).
All Patients (n  16)
Toxicity
Grade
1 2 3 4
All patients (n  16)
Alopecia 6 (38%) 1 (6%) N/A N/A
Anemia 0 (0%) 0 (0%) 1 (6%) 0 (0%)
Dry eyes 2 (13%) 0 (0%) 0 (0%) 0 (0%)
Epistaxis 9 (56%) 0 (0%) 0 (0%) 0 (0%)
Fatigue 8 (50%) 7 (44%) 0 (0%) 0 (0%)
Lymphopenia 0 (0%) 0 (0%) 4 (25%) N/A
Nausea 3 (19%) 1 (6%) 1 (6%) 0 (0%)
Skin 2 (13%) 3 (19%) 1 (6%) 0 (0%)
Stomatitis 0 (0%) 3 (19%) 8 (50%) 1 (6%)
Vomiting 0 (0%) 1 (6%) 0 (0%) 0 (0%)
Patients without vitamin
supplementation (n  9)
Alopecia 5 (56%) 1 (11%) N/A N/A
Anemia 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Dry eyes 1 (11%) 0 (0%) 0 (0%) 0 (0%)
Epistaxis 5 (56%) 0 (0%) 0 (0%) 0 (0%)
Fatigue 5 (56%) 4 (44%) 0 (0%) 0 (0%)
Lymphopenia 0 (0%) 0 (0%) 1 (11%) N/A
Nausea 2 (22%) 1 (11%) 1 (11%) 0 (0%)
Skin 2 (22%) 2 (22%) 1 (11%) 0 (0%)
Stomatitis 0 (0%) 3 (33%) 5 (56%) 1 (11%)
Vomiting 0 (0%) 1 (6%) 0 (0%) 0 (0%)
Patients with vitamin
supplementation (n  7)
Alopecia 1 (14%) 0 (0%) N/A N/A
Anemia 0 (0%) 0 (0%) 1 (14%) 0 (0%)
Dry eyes 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Epistaxis 4 (57%) 0 (0%) 0 (0%) 0 (0%)
Fatigue 3 (43%) 3 (43%) 0 (0%) 0 (0%)
Lymphopenia 0 (0%) 0 (0%) 3 (43%) N/A
Nausea 1 (14%) 0 (0%) 0 (0%) 0 (0%)
Skin 0 (0%) 1 (14%) 0 (0%) 0 (0%)
Stomatitis 0 (0%) 0 (0%) 3 (43%) 0 (0%)
Vomiting 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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in non-small cell lung cancer, half of the patients treated
without vitamin supplementation at the same dose and sched-
ule had no stomatitis.12
Pralatrexate administered at other doses or schedules
may yield more favorable results, and these are being ex-
plored. In the original phase I study of pralatrexate,11 admin-
istration on a weekly schedule without vitamin supplementa-
tion resulted in dose-limiting stomatitis at only 30 mg/m2, so
the biweekly schedule was subsequently pursued. However,
significant clinical activity has been observed in patients with
refractory T-cell lymphoma treated with pralatrexate on a
weekly schedule with the addition of vitamins.18 In addition,
a phase I dose escalation trial of pralatrexate with vitamin
supplementation is ongoing in patients with non-small cell
lung cancer, including pharmacokinetics and measurements
of vitamin concentrations, to determine whether these factors
can predict the risk of toxicity. Based on preclinical data,9
combinations with platinum agents may also be of interest.
Nonetheless, with the dose and schedule used in this phase II
study, pralatrexate showed a lack of response in mesotheli-
oma and significant toxicity, even in patients who received
folic acid and B12.
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